摘要
Abstract
Objective To evaluate the clinical efficacy and safety of montelukast sodium combined with budesonide in the treatment of child-hood asthma.Methods Eighty -four patients with childhood asthma were randomly divided into control group ( n=42 ) and treatment group (n=42).Control group was treated with budesonide 200 μg, qd. Treatment group was received budesonide 200 μg, qd and montelukast sodium 4 mg・ d-1 ( 3 -6 years ) , 5 mg・ d-1 ( 6 -14 years ) , every night.The treatment of two groups was 3 months, and follow up for 3 months. During the treatment , two groups were received compound ipratropium bromide 200 μL・ d-1 (3-6 years), 400 μL・ d-1 (6-14 years ) for acute asthma attack , continuous days depending on the severity of the disease.The clinical efficacy, lung function, levels of total serum immunoglobulin E(IgE), acute attacks of asthma, the use of compound ipratropium bromide , and the incidence of adverse drug reactions were compared between two groups. Results After treatment, the total efficacy rates of treatment group was 92.86%, which was significantly higher than 73.81% in control group ( P <0.05 ) .The degrees of the improvement of lung function and the decrease of the levels of total serum IgE in treatment group were significantly bet -ter than those in control group(P<0.05).During the treatment, the acute attacks of asthma and the days of use com-pound ipratropium bromide in treatment group were significantly less than those in the control group ( P<0.05 ).There was no significant difference with incidence of adverse drug reactions between two groups ( P>0.05 ) .Conclusion Montelukast sodium combined with budesonide have a definitive clinical efficacy for the treatment of childhood asthma , which may improve lung function and total serum IgE , and without increasing the incidence of adverse drug reactions .关键词
孟鲁司特钠/布地奈德/复方异丙托溴铵/儿童哮喘/血清总免疫球蛋白EKey words
montelukast sodium/budesonide/compound isopropyl bromide/childhood asthma/total serum immunoglobulin E分类
医药卫生
